Use of antidementia agents in vascular dementia: Beyond Alzheimer disease

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Vascular dementia (VaD) is the second leading cause of dementia and is often underdiagnosed. Stroke is the leading cause of VaD, although it may also develop secondary to a variety of other cerebrovascular or cardiovascular conditions. Currently, no drugs are approved for the treatment of VaD. However, because cholinergic deficits have been found to patients with VaD, similar to those found in patients with Alzheimer disease (AD), it is believed that cholinesterase inhibitors, which are indicated for the treatment of mild to moderate AD, may also provide benefit for patients with VaD. Clinical trials of donepezil, galantamine, and rivastigmine have supported this idea, although as yet, large-scale, prospective studies in VaD have only been reported for donepezil. Donepezil was shown to provide benefits in cognition, global function, and activities of daily living compared with placebo. The N-methyl-D-aspartate receptor antagonist memantine may also provide some cognitive benefit in VaD, particularly in patients with more advanced disease. These data suggest that antidementia drugs currently used for treatment of AD should be considered for treatment of VaD as well.

Original languageEnglish
Pages (from-to)1350-1358
Number of pages9
JournalMayo Clinic Proceedings
Volume81
Issue number10
DOIs
StatePublished - 2006

Fingerprint

Vascular Dementia
Alzheimer Disease
Rivastigmine
Galantamine
Memantine
Cholinesterase Inhibitors
Therapeutics
Activities of Daily Living
N-Methyl-D-Aspartate Receptors
Pharmaceutical Preparations
Cognition
Cholinergic Agents
Dementia
Stroke
Placebos
Clinical Trials
Prospective Studies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Use of antidementia agents in vascular dementia : Beyond Alzheimer disease. / Farlow, Martin.

In: Mayo Clinic Proceedings, Vol. 81, No. 10, 2006, p. 1350-1358.

Research output: Contribution to journalArticle

@article{f0dc73966cd346f08426595f7d801932,
title = "Use of antidementia agents in vascular dementia: Beyond Alzheimer disease",
abstract = "Vascular dementia (VaD) is the second leading cause of dementia and is often underdiagnosed. Stroke is the leading cause of VaD, although it may also develop secondary to a variety of other cerebrovascular or cardiovascular conditions. Currently, no drugs are approved for the treatment of VaD. However, because cholinergic deficits have been found to patients with VaD, similar to those found in patients with Alzheimer disease (AD), it is believed that cholinesterase inhibitors, which are indicated for the treatment of mild to moderate AD, may also provide benefit for patients with VaD. Clinical trials of donepezil, galantamine, and rivastigmine have supported this idea, although as yet, large-scale, prospective studies in VaD have only been reported for donepezil. Donepezil was shown to provide benefits in cognition, global function, and activities of daily living compared with placebo. The N-methyl-D-aspartate receptor antagonist memantine may also provide some cognitive benefit in VaD, particularly in patients with more advanced disease. These data suggest that antidementia drugs currently used for treatment of AD should be considered for treatment of VaD as well.",
author = "Martin Farlow",
year = "2006",
doi = "10.4065/81.10.1350",
language = "English",
volume = "81",
pages = "1350--1358",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "10",

}

TY - JOUR

T1 - Use of antidementia agents in vascular dementia

T2 - Beyond Alzheimer disease

AU - Farlow, Martin

PY - 2006

Y1 - 2006

N2 - Vascular dementia (VaD) is the second leading cause of dementia and is often underdiagnosed. Stroke is the leading cause of VaD, although it may also develop secondary to a variety of other cerebrovascular or cardiovascular conditions. Currently, no drugs are approved for the treatment of VaD. However, because cholinergic deficits have been found to patients with VaD, similar to those found in patients with Alzheimer disease (AD), it is believed that cholinesterase inhibitors, which are indicated for the treatment of mild to moderate AD, may also provide benefit for patients with VaD. Clinical trials of donepezil, galantamine, and rivastigmine have supported this idea, although as yet, large-scale, prospective studies in VaD have only been reported for donepezil. Donepezil was shown to provide benefits in cognition, global function, and activities of daily living compared with placebo. The N-methyl-D-aspartate receptor antagonist memantine may also provide some cognitive benefit in VaD, particularly in patients with more advanced disease. These data suggest that antidementia drugs currently used for treatment of AD should be considered for treatment of VaD as well.

AB - Vascular dementia (VaD) is the second leading cause of dementia and is often underdiagnosed. Stroke is the leading cause of VaD, although it may also develop secondary to a variety of other cerebrovascular or cardiovascular conditions. Currently, no drugs are approved for the treatment of VaD. However, because cholinergic deficits have been found to patients with VaD, similar to those found in patients with Alzheimer disease (AD), it is believed that cholinesterase inhibitors, which are indicated for the treatment of mild to moderate AD, may also provide benefit for patients with VaD. Clinical trials of donepezil, galantamine, and rivastigmine have supported this idea, although as yet, large-scale, prospective studies in VaD have only been reported for donepezil. Donepezil was shown to provide benefits in cognition, global function, and activities of daily living compared with placebo. The N-methyl-D-aspartate receptor antagonist memantine may also provide some cognitive benefit in VaD, particularly in patients with more advanced disease. These data suggest that antidementia drugs currently used for treatment of AD should be considered for treatment of VaD as well.

UR - http://www.scopus.com/inward/record.url?scp=33749263352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749263352&partnerID=8YFLogxK

U2 - 10.4065/81.10.1350

DO - 10.4065/81.10.1350

M3 - Article

C2 - 17036561

AN - SCOPUS:33749263352

VL - 81

SP - 1350

EP - 1358

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 10

ER -